Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial

Huijie Bian, Liang Chen, Zhao Hui Zheng, Xiu Xuan Sun, Jie Jie Geng, Ruo Chen, Ke Wang, Xu Yang, Shi Rui Chen, Si Yu Chen, Rong Hua Xie, Kui Zhang, Jin Lin Miao, Jun Feng Jia, Hao Tang, Shuang Shuang Liu, Hong Wei Shi, Yong Yang, Xiao Chun Chen, Vinay MalhotraNosheen Nasir, Iffat Khanum, Faisal Mahmood, Saeed Hamid, Claudio Marcel Berdun Stadnik, Kengi Itinose, Caroline Cândida Carvalho de Oliveira, Cesar Dusilek, Lucas Rivabem, Adilson Joaquim Westheimer Cavalcante, Suzara Souto Lopes, Wladmir Faustino Saporito, Fábio José Concilio Fucci, Jesus Abraham Simon-Campos, Ling Wang, Lin Na Liu, Qing Yi Wang, Ding Wei, Zheng Zhang, Zhi Nan Chen, Ping Zhu

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology